IMCR News and Press, Immunocore Holdings plc From 11/30/23

Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-cla...

2023-11-25 16:32:53 ET More on BioCryst Pharmaceuticals, Crinetics Pharmaceuticals, etc. Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript Immunocore: First Half Of 2024 IMC-F106...

2023-11-17 18:40:33 ET Summary Delcath's Hepzato Kit is the only liver directed FDA approved treatment for mUM, a rare form of cancer. It will launch in the US in January. The treatment had a 36.3% objective response rate, outperforming the best available alternative treatment by ...

Immunocore Holdings plc (IMCR) is expected to report $-0.32 for Q3 2023

2023-11-07 08:24:26 ET More on Immunocore Immunocore: First Half Of 2024 IMC-F106C Data Expected Immunocore: KIMMTRAK Adoption Continues At Rapid Pace, Expanding To New Markets, Reiterate Buy Immunocore Holdings plc (IMCR) Q2 2023 Earnings Call Transcript Bai...

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major markets with continued reimbursement expansion globally New Phase 3 clinical trial of K...

2023-11-01 17:42:17 ET Summary Immunocore Holdings plc had net KIMMTRAK product revenues of $57.8 million generated in Q2 2023. Release of results from phase 1/2 study, using IMC-F106C for the treatment of various cancers, expected in the first half of 2024. Initiation of phas...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 01 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad ran...

2023-10-31 14:15:41 ET More on Immunocore Immunocore: KIMMTRAK Adoption Continues At Rapid Pace, Expanding To New Markets, Reiterate Buy Immunocore Holdings plc (IMCR) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Immunocore Historic...

Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01 positive patients with previously untreated metastatic uveal melanoma (OXFORDSHIRE...